AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $1.84 billion. The enterprise value is $1.81 billion.
Important Dates
The next confirmed earnings date is Tuesday, February 17, 2026, after market close.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 49.72 million shares outstanding. The number of shares has increased by 1.59% in one year.
| Current Share Class | 49.72M |
| Shares Outstanding | 49.72M |
| Shares Change (YoY) | +1.59% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 99.16% |
| Float | 47.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.46 |
| Forward PS | 3.16 |
| PB Ratio | 3.94 |
| P/TBV Ratio | 9.80 |
| P/FCF Ratio | 56.90 |
| P/OCF Ratio | 43.53 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 54.74 |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.87 |
| Quick Ratio | 2.71 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.33 |
| Interest Coverage | -4.54 |
Financial Efficiency
Return on equity (ROE) is -6.11% and return on invested capital (ROIC) is -6.38%.
| Return on Equity (ROE) | -6.11% |
| Return on Assets (ROA) | -2.65% |
| Return on Invested Capital (ROIC) | -6.38% |
| Return on Capital Employed (ROCE) | -4.75% |
| Weighted Average Cost of Capital (WACC) | 11.75% |
| Revenue Per Employee | $398,696 |
| Profits Per Employee | -$22,132 |
| Employee Count | 1,300 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, AtriCure has paid $947,000 in taxes.
| Income Tax | 947,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.29% in the last 52 weeks. The beta is 1.41, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -11.29% |
| 50-Day Moving Average | 38.86 |
| 200-Day Moving Average | 35.12 |
| Relative Strength Index (RSI) | 43.15 |
| Average Volume (20 Days) | 505,483 |
Short Selling Information
The latest short interest is 2.37 million, so 4.76% of the outstanding shares have been sold short.
| Short Interest | 2.37M |
| Short Previous Month | 2.50M |
| Short % of Shares Out | 4.76% |
| Short % of Float | 4.93% |
| Short Ratio (days to cover) | 4.91 |
Income Statement
In the last 12 months, AtriCure had revenue of $518.31 million and -$28.77 million in losses. Loss per share was -$0.61.
| Revenue | 518.31M |
| Gross Profit | 388.06M |
| Operating Income | -26.46M |
| Pretax Income | -27.83M |
| Net Income | -28.77M |
| EBITDA | -6.21M |
| EBIT | -26.46M |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $147.87 million in cash and $76.73 million in debt, with a net cash position of $71.14 million or $1.43 per share.
| Cash & Cash Equivalents | 147.87M |
| Total Debt | 76.73M |
| Net Cash | 71.14M |
| Net Cash Per Share | $1.43 |
| Equity (Book Value) | 476.51M |
| Book Value Per Share | 9.59 |
| Working Capital | 223.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $43.14 million and capital expenditures -$10.14 million, giving a free cash flow of $33.00 million.
| Operating Cash Flow | 43.14M |
| Capital Expenditures | -10.14M |
| Free Cash Flow | 33.00M |
| FCF Per Share | $0.66 |
Full Cash Flow StatementMargins
Gross margin is 74.87%, with operating and profit margins of -5.11% and -5.55%.
| Gross Margin | 74.87% |
| Operating Margin | -5.11% |
| Pretax Margin | -5.37% |
| Profit Margin | -5.55% |
| EBITDA Margin | -1.20% |
| EBIT Margin | -5.11% |
| FCF Margin | 6.37% |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.59% |
| Shareholder Yield | -1.59% |
| Earnings Yield | -1.53% |
| FCF Yield | 1.76% |
Analyst Forecast
The average price target for AtriCure is $52.22, which is 40.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $52.22 |
| Price Target Difference | 40.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 13.98% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 6.5 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.5 |
| Piotroski F-Score | 5 |
